Clinical Scorecard: May OPO Perfusion Expand Liver Use?
At a Glance
| Category | Detail |
|---|---|
| Condition | Liver transplantation using higher-risk donor organs |
| Key Mechanisms | Portable hypothermic oxygenated machine perfusion (HMP-O2) |
| Target Population | Patients receiving liver transplants from donation-after-circulatory-death donors and other high-risk donors |
| Care Setting | Organ procurement organization and transplant centers |
Key Highlights
- 100% patient and graft survival at a median follow-up of 449 days
- 67% of donors were donation-after-circulatory-death
- Median cold ischemia time was 582 minutes
- No cases of ischemic cholangiopathy or primary nonfunction observed
- Posttransplant outcomes similar between organ procurement organization and transplant center groups
Guideline-Based Recommendations
Diagnosis
- Evaluate donor organ suitability using HMP-O2
Management
- Implement portable HMP-O2 initiated by trained organ procurement organization staff
Monitoring & Follow-up
- Monitor for early allograft dysfunction and biliary complications post-transplant
Risks
- Potential for early bile leak, anastomotic biliary stricture, and acute cellular rejection
Patient & Prescribing Data
Patients undergoing liver transplantation from higher-risk donors
HMP-O2 may improve outcomes in complex donor organ transplants
Clinical Best Practices
- Train organ procurement organization staff for HMP-O2 implementation
- Consider longer preservation times in organ procurement organization protocols
- Ensure monitoring for complications post-transplant
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
